UY28203A1 - Formulaciones de glucocorticoides para el tratamiento de la angiogenesis ocular patologica. - Google Patents

Formulaciones de glucocorticoides para el tratamiento de la angiogenesis ocular patologica.

Info

Publication number
UY28203A1
UY28203A1 UY28203A UY28203A UY28203A1 UY 28203 A1 UY28203 A1 UY 28203A1 UY 28203 A UY28203 A UY 28203A UY 28203 A UY28203 A UY 28203A UY 28203 A1 UY28203 A1 UY 28203A1
Authority
UY
Uruguay
Prior art keywords
glucocorticoids
formulations
treatment
ocular angiogenesis
pathological ocular
Prior art date
Application number
UY28203A
Other languages
English (en)
Inventor
David P Bingaman
Abbot F Clark
Rajni Jani
Stella M Robertson
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of UY28203A1 publication Critical patent/UY28203A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las formulaciones de glucocorticoides solos y en combinación con acetato de anecortave son útiles para prevenir y tratar la angiogénesis ocular patológica y los edemas asociadosl
UY28203A 2003-02-20 2004-02-19 Formulaciones de glucocorticoides para el tratamiento de la angiogenesis ocular patologica. UY28203A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44894403P 2003-02-20 2003-02-20

Publications (1)

Publication Number Publication Date
UY28203A1 true UY28203A1 (es) 2004-08-31

Family

ID=32908675

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28203A UY28203A1 (es) 2003-02-20 2004-02-19 Formulaciones de glucocorticoides para el tratamiento de la angiogenesis ocular patologica.

Country Status (16)

Country Link
US (2) US20060074061A1 (es)
EP (1) EP1594511A2 (es)
JP (2) JP2006518383A (es)
KR (1) KR20050102653A (es)
CN (1) CN100431544C (es)
AR (1) AR043252A1 (es)
AU (1) AU2004212900A1 (es)
BR (1) BRPI0407742A (es)
CA (1) CA2516790A1 (es)
MX (1) MXPA05008396A (es)
PL (1) PL378209A1 (es)
RU (1) RU2005129278A (es)
TW (1) TW200507858A (es)
UY (1) UY28203A1 (es)
WO (1) WO2004073608A2 (es)
ZA (1) ZA200505990B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032510A1 (en) * 2003-09-23 2005-04-14 Alcon, Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US7257366B2 (en) * 2003-11-26 2007-08-14 Osmosis Llc System and method for teaching a new language
EP1931387A4 (en) * 2005-09-07 2012-07-11 Southwest Res Inst BIODEGRADABLE MICROTEILED PHARMACEUTICAL FORMULATIONS WITH IMPROVED RELEASE RATES
US9693967B2 (en) 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US20070149616A1 (en) * 2005-12-22 2007-06-28 Alcon Manufacturing, Ltd. C3-Convertase Inhibitors for the Prevention and Treatment of Age-Related Macular Degeneration in Patients With At Risk Variants Of Complement Factor H
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
GB0625844D0 (en) * 2006-12-22 2007-02-07 Daniolabs Ltd The treatment of macular degeneration
CA2693888A1 (en) * 2007-07-20 2009-01-29 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
JP6148175B2 (ja) * 2010-05-10 2017-06-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 網膜中および／または網膜下における液体貯留の処置のための方法および組成物
CA2951721C (en) * 2014-06-12 2023-09-26 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5556848A (en) * 1993-12-27 1996-09-17 Senju Pharmaceutical Co., Ltd. Ophthalmic suspension containing diflupredonate
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
ES2231257T3 (es) * 1999-10-21 2005-05-16 Alcon Inc. Dispositivo para la administracion de farmacos.
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
MXPA02002376A (es) * 1999-10-21 2002-08-28 Alcon Universal Ltd Entrega de droga al sub-tenon-.
US20060166956A1 (en) * 2002-08-05 2006-07-27 Jerdan Janice A Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration

Also Published As

Publication number Publication date
AR043252A1 (es) 2005-07-20
AU2004212900A1 (en) 2004-09-02
EP1594511A2 (en) 2005-11-16
WO2004073608A3 (en) 2005-03-24
WO2004073608A2 (en) 2004-09-02
JP2006518383A (ja) 2006-08-10
US20060074061A1 (en) 2006-04-06
JP2007056041A (ja) 2007-03-08
ZA200505990B (en) 2006-12-27
RU2005129278A (ru) 2006-01-27
MXPA05008396A (es) 2006-03-30
CN1750829A (zh) 2006-03-22
KR20050102653A (ko) 2005-10-26
BRPI0407742A (pt) 2006-02-14
TW200507858A (en) 2005-03-01
PL378209A1 (pl) 2006-03-20
CN100431544C (zh) 2008-11-12
CA2516790A1 (en) 2004-09-02
US20040167109A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
TR200102817T2 (tr) Antiinflamatuar ajanlar olarak faydalı bileşikler
WO2004106486A3 (en) Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
DOP2006000252A (es) Profarmacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y metodos
SV2006002283A (es) Formulaciones
MX2007016462A (es) Composiciones topicas para tratar la piel.
UY26186A1 (es) Inhibidores de metaloproteasas
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
UY29238A1 (es) Formulaciones de nepafenac para su administracion topica
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
DE50312034D1 (de) Liposomale glucocorticoide
UY28203A1 (es) Formulaciones de glucocorticoides para el tratamiento de la angiogenesis ocular patologica.
PE20050477A1 (es) Terapia de combinacion para la infeccion de hcv
ECSP055823A (es) DERIVADOS DE [6,7-DIHIDRO-5H-IMIDAZO[1,2-a]IMIDAZOL-3-SULFONILAMINO]-PROPIONAMIDA
AR040130A1 (es) Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos
CL2008000495A1 (es) Compuestos derivados de tetrahidro-pirazolo[4,3-c]piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alergias, inflamacion, dolor, cancer, entreotras.
AR045943A1 (es) Formulaciones de acetonido de triamcinolona y acetato de anecortave para inyeccion
DE602004013035D1 (de) Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung
TW200509896A (en) Analeptic and drug combinations
DK0869965T3 (da) Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.
GT200400241A (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos8b-vinil-estra-1,3,5,(10)-trien-3,17b-diol y 17b-fluor-9a-vinil-estra-1,3,6,(10)-trien-3, 16a-diol
AR051844A1 (es) Uso de agonistas beta de estrogenos en desordenes o enfermedades cognitivas
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140818